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Background: Since December 2009 a new VMAT planning system tool is available in OncentraW MasterPlan v3.3
(Nucletron B.V.). The purpose of this study was to work out standard parameters for the optimization of prostate
cancer.
Methods: For ten patients with localized prostate cancer plans for simultaneous integrated boost were optimized,
varying systematically the number of arcs, collimator angle, the maximum delivery time, and the gantry spacing.
Homogeneity in clinical target volume, minimum dose in planning target volume, median dose in the organs at
risk, maximum dose in the posterior part of the rectum, and number of monitor units were evaluated using
student’s test for statistical analysis. Measurements were performed with a 2D-array, taking the delivery time, and
compared to the calculation by the gamma method.
Results: Plans with collimator 45° were superior to plans with collimator 0°. Single arc resulted in higher minimum
dose in the planning target volume, but also higher dose values to the organs at risk, requiring less monitor units
per fraction dose than dual arc. Single arc needs a higher value (per arc) for the maximum delivery time parameter
than dual arc, but as only one arc is needed, the measured delivery time was shorter and stayed below 2.5 min
versus 3 to 5 min. Balancing plan quality, dosimetric results and calculation time, a gantry spacing of 4° led to
optimal results.
Conclusion: A set of parameters has been found which can be used as standard for volumetric modulated arc
therapy planning of prostate cancer.
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Volumetric modulated arc therapy (VMAT) is a rather
novel form of radiotherapy delivery, varying multi leaf col-
limator (MLC) shape, dose rate and gantry speed simul-
taneously during gantry rotation. Otto presented this
technique in 2008 [1]. Up to that date intensity modulated
radiation therapy (IMRT) had emerged as a standard tech-
nique for radiotherapy of the prostate [2-6]. Shorter
treatment times, which are desirable with regard to intra-
fractional organ motion, are possible with VMAT [1,7-10].
A few studies have been published comparing IMRT and
VMAT for prostate radiotherapy [11-15]. All of them used
data of Varian accelerators with its implementation of
VMAT called RapidArcW (Varian Medical Systems, Inc.,* Correspondence: marius.treutwein@ukr.de
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reproduction in any medium, provided the orUSA) and either prototypes of planning or optimizing sys-
tems or Varian’s Eclipse™. Otto stated that the ability to
generate complex dose distributions is highly dependent
on the optimization algorithm and capabilities of the de-
livery system used for treatment [16,17]. A new system
combination of two other manufacturers became clinically
available for VMAT in December 2009: a VMAT treat-
ment planning tool implemented in OncentraW Master-
Plan v3.3 (Nucletron B.V., Veenendal, The Netherlands),
and the VMAT implementation on a SynergyWS linac
(Elekta Ltd, Crawley, UK). First results achieved with this
system combination have been published for a limited
number of patients [18,19]. Planning studies with statis-
tical significance are, however, not yet available.
The aim of our study was to assess the potential of this
new system combination for VMAT of prostate cancer.
The treatment planning was performed for a simultaneousral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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variation of the user defineable parameters was performed
to identify the influence of the different parameters on
plan quality, treatment time and monitor units (MU). A
detailed evaluation of 360 treatment plans allowed the
deduction of the optimal parameter set for VMAT
optimization with statistical significance.
Methods
Patients and regions of interest (ROI)
Ten consecutive patients with a mean age of 71 years,
which had been treated with primary external-beam
radiotherapy for localized prostate cancer, were included
in the retrospective planning study. Written informed
consent was obtained from the patients for publication
of this report and any accompanying images. All ten
patients were immobilized in a vacuum mattress (Blue-
BAG™ BodyFIXW, Medical Intelligence, Schwabmünchen,
Germany) in supine position according to Boehmer et al.
[20] and had three-dimensional treatment planning with
a CT slice thickness of 5 mm. In the treatment-planning
system OncentraW MasterPlan, v3.3 (Nucletron B.V.,
Veenendaal, The Netherlands) the gross target volume
(GTV: prostate gland and seminal vesicles), the clinical
target volume (CTV, 5-mm three-dimensional margin
added to the GTV excluding the rectal volume),
the planning target volume (PTV, 10-mm three -
dimensional margin added to the GTV without respect
to the rectum), and normal tissues were delineated in
each slice. The delineation of the volumes of interest fol-
lowed the description of Bos et al. [21], who also showed
that a little overlap of PTV and rectum results from the
lateral expansion of the PTV. The rectal volume
(according to Guckenberger et al. [22]) and urinary blad-
der as well as the femoral heads were delineated as
organs at risk (OAR). Additional regions were defined to
improve the plan quality: the PTV plus a margin of
5 mm (PTVm) was first subtracted from the patient out-
line (OL) for a non target volume (OL-PTVm) to avoid
hot spots in the normal tissue; It was second subtracted
from the rectum volume resulting in the posterior part
of the rectum (R-PTVm) to achieve reduced dose in this
region as similarly described in [12]. The last structure
constructed was PTV minus CTV (PTV-CTV) to model
the dose gradient from PTV to CTV.
Linear accelerator
For planning and measurements the data of a SynergyWS
linear accelerator (Elekta Ltd, Crawley, United Kingdom)
with 6MV photons were used, equipped with a Beam-
Modulator™ head, an iViewGT™ electronic portal im-
aging device, and an on-board cone-beam CT XVI. The
multileaf collimator has 40 leaf pairs, each of nominal
width of 4 mm projected to isocentre, diaphragms limitthe maximum field size of 21 cm×16 cm. There are no
moveable jaws. Leaf interdigitation is allowed without
limitations, which means that each leaf can travel across
the whole field size, independent on the position of
neighbouring leaves. Closed leaf pairs are automatically
shifted below the fixed diaphragm to minimize transmis-
sion between the leaf ends of opposed leaves.
The following linac specific parameters for VMAT de-
livery have to be fed into the planning system as
described similar for Eclipse™ and RapidArcW [23]:
Minimum and maximum number of MU per degree
of gantry rotation 0.10 MU/° and 20.0 MU/° respectively,
minimum MU per cm leaf travel 0.30 MU/cm, max-
imum gantry speed 6.00°/s. Maximum leaf speed is
2.4 cm/s, the dynamic minimum leaf gap 0.2 cm, and
the static minimum leaf gap 0.0 cm [24]. The maximum
nominal dose rate is 500 MU/min. Seven fixed dose rate
levels are available, each half the dose rate of the next
higher level, continuous variation is not possible. Actual
dose rates may differ from nominal dose rates by ±25%.
For VMAT delivery the console software Precise Desk-
topW 7 determines automatically the fastest combination
of dose rate, gantry speed and leaf speed [19].
Treatment planning system (TPS)
The treatment planning was performed with Oncentra
MasterPlanW v3.3 SP1, released clinically in December
2009, on a 64 bit Windows system. From the above
mentioned data the two lowest dose rate levels had to be
omitted, as the TPS allows only five different levels [19].
In the Beam Modeling module the user appoints only
the treatment unit, the number of beams, the energy
and the collimator angle. Although the linac could vary
the collimator angle during VMAT delivery this feature
is not implemented in the current TPS software version.
Switching to the Optimizer module the user has further
parameters to determine: gantry start angle, rotation dir-
ection, arc length, gantry angle spacing between subse-
quent control points (2°, 3°, 4°, or 6°), maximum delivery
time (MDT), number of arcs, and leaf motion constraint
in cm/°, which was set to 0.5 cm/°. The optimizer called
RayArc has been developed by RaySearch and is
described in [25] and in a White Paper [26]. RayArc is
designed to create deliverable plans for Elekta and
Varian machines. It exists in two versions, as SmartArc
module integrated in Pinnacle³ Version 9 (Philips
Healthcare, The Netherlands) and the mentioned
Oncentra version.
Planning
The plans were set up with simultaneous integrated
boost (SIB) in 33 fractions aiming for 59.4 Gy minimum
dose to the PTV and 71.0 Gy minimum dose and
74.2 Gy maximum dose to the CTV, which was used as
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[25] (with little modifications) the same set of dose vol-
ume objectives (DVO) was used (Table 1) for all VMAT
and IMRT plans, based on experiences with the same
optimization module for IMRT [27]. The DVO are set as
planning goals to be met if possible. As Dobler et al.
[28] stated it might be possible to achieve better plan
quality using DVO specifically designed for the algo-
rithm and delivery method. However, a direct compari-
son of results would be impossible.
The isocentre was positioned in the centre of the CTV.
All calculations were performed by a pencil beam algo-
rithm with a calculation grid spacing of 4 mm. Both the
slice thickness of 5 mm and the calculation grid spacing of
4 mm were rather coarse regarding a leaf width of 4 mm.
The reason is that the main memory of the hardware was
too small to handle a better resolution in the optimization
process. To verify that there was no misinterpretation by
interpolation, for a subset of ten different plans, one for
each patient, a forward calculation was done with a finer

















































Dose volume objectives and their weights used in the objective function
during the optimization process.2.5 mm was generated by means of the TPS. The calcula-
tion grid spacing was set to 2 mm. All plans were forward
calculated without new optimization and without any
change. There was either no change, or the values shifted
slightly for all plans systematically to the same direction,
keeping the general conclusion unchanged.
Altogether 360 plans were calculated, 36 per patient.
The following parameters were varied systematically for
each patient:
Single versus dual arc
Besides the option to deliver the treatment in a single
arc (SA), it is also possible to choose two or multiple
arcs. They can be used as two “independent” arcs or as
dual arc (DA). As Dobler et al. [19] and Eriksson et al.
[26] have described, for targets divided by an OAR in a
left and a right side (as given by prostate and rectum) in
the DA mode one arc will focus to the left and one to
the right side, reducing the leaf openings over the OAR
and thereby the dose delivered to it. Two independent
arcs on the other hand would both produce similar seg-
ments around the arc. Therefore SA and DA were the
chosen alternatives in our study both rotating from 182°
to 178° respectively bidirectional.
Collimator angle
Otto stated [1] and confirmed later [16] that 45° collima-
tor angle has been found to be preferable in most cases.
Bortfeld [29] comments on this question that it is not
completely clear where the advantage of a 45° collimator
comes from. In [30] Bortfeld and Webb have done their
calculations with a collimator angle of 0° confining to a
2D model. Otto [16] extended the analysis to the cap-
abilities of RapidArcW including a collimator angle of
45°. Since this still seems to be analyzed only theoretic-
ally, all plan optimizations were performed for collima-
tor 45° and 0°.
Maximum delivery time
The MDT is an optimization parameter allowing the
user to make a delivery time restriction. It is only an es-
timate for the real delivery time, as gantry speed and
dose rate values are determined by the console software
using the control point information [25]. Due to limita-
tions in gantry speed of 6.00°/s, a rotation around 356°
requires at least 59.3 s. To allow some more time for
modulation a minimum value per arc of 80 s was
chosen, slightly more than recommended by Eriksson
et al. [26] (75 s). As a medium value we selected 110 s
and as maximum value 150 s.
Gantry spacing
The gantry spacing (GS) between two subsequent con-
trol points is reduced during the optimization process.
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points are added to achieve the final GS selected by the
user [31]. As Eriksson et al. [26] recommend to start
with a spacing of 4 degrees, we decided to increase and
decrease to the extreme values possible in the TPS and
used three different GS: 2°, 4°, and 6°. These are also
the values which Feygelman et al. [32] used for their
SmartArc evaluation and allow comparison to their
results.
IMRT
For comparison one IMRT plan was calculated for each
patient applying direct step and shoot optimization also
using the DVO of Table 1. The collimator was in stand-
ard position of 0°. The planning parameters followed
Treutwein et al. [27]: seven equispaced beams, starting
at a gantry angle of 0°, followed by 51°, 103°, 154°, 206°,
257° and 309°; minimum field size of 4 cm², at least two
open leaf pairs, maximum number of 60 segments and
minimum 4 MU per segment.
Plan evaluation and statistics
Besides the median values in the OAR the following
parameters were evaluated: the total number of MU, the
homogeneity H and D5 and D95 in the CTV with H
defined as H= (D5–D95)/DAverage [33,34]. D5 and D95 are
defined as the dose to 5% and 95% of the CTV, respect-
ively. Furthermore the maximum dose to the posterior
part of the rectum and the minimum dose in the PTV
were analyzed as endpoints of the optimization. The
results of all plans were grouped according to the modi-
fied parameters and analyzed statistically using SPSS
PASW Statistics programme version 18.0.0. Groups were
compared applying student’s test (t-test) for paired sam-
ples. As level of significance α= 5% (two-sided) was
chosen. To obtain a good statistical significance as few
groups of plans as possible were established for each
parameter.
Moreover all plans meeting the endpoints mentioned
above were selected and the incidence in the different
groups was determined.
Plan verification
Five groups of VMAT plans and the IMRT group contain-
ing ten plans for the different patients each were mea-
sured with a MatriXX EvolutionW 2D-array with gantry
angle sensor (IBA Dosimetry, Schwarzenbruck, Germany)
[35,36] positioned in the horizontal isocentre plane. The
gantry angle sensor was attached to the gantry and con-
nected to the array. Every 200 ms a dose matrix and the
corresponding gantry angle were acquired automatically.
The matrices were corrected for angular dependencies, in-
cluding couch attenuation as described in [35], using a
correction factor matrix implemented in the software.Lastly they were summed up to the dose of the complete
plan. This was compared to the calculated dose matrices
by gamma evaluation [37] with a dose tolerance of 3% of
the maximum dose and a distance to agreement of 3 mm.
We performed the evaluation for the area with dose values
above 10% as recommended in [38]. The percentage of
pixels out of range (γ> 1) was analyzed. In addition radi-
ation times were measured from pressing the start button
to end of delivery.
Results
Plan evaluation
All results are shown in Table 2; significant differences
between groups are described in the corresponding sec-
tions. On behalf of brevity, differences and correspond-
ing p-values are not mentioned if not statistically
significant except of an intermediate range (α= 10%),
otherwise they are described as significant (α= 5%) or
highly significant (α= 1%).
The median dose to the femoral heads in a range from
24.5 Gy to 33.4 Gy as average for the subgroups of ten
patient plans stayed far below the DVO of 50 Gy.
According to Kjær-Kristoffersen et al. [13] this param-
eter was disregarded furthermore.
Single versus dual arc
All plans with SA optimization were gathered in one group
and compared to the corresponding plans with DA result-
ing in 180 pairs of plans. Differences between SA and DA
were highly significant for the following parameters: SA
resulted in higher minimum dose in the PTV requiring less
MU per fraction dose than DA. On the other hand the
maximum dose to the posterior rectum, the median dose
to the complete rectum and the median dose to the urinary
bladder were highly significant reduced for DA. Both
groups contained 37 plans fulfilling the DVO.
Collimator angle
All plans with collimator 0° were combined in one group
and compared to the corresponding plans with collima-
tor 45° giving 180 pairs of plans. Plans with collimator
45° had a highly significant improvement in the follow-
ing parameters: homogeneity to the CTV, minimum
dose to the PTV, maximum dose to the posterior rec-
tum, and MU per fraction. A majority of 48 plans with
collimator 45° met the DVO, but only 26 plans with col-
limator 0°.
Maximum delivery time
As the chosen value for MDT limits the time per arc the
plans with SA and with DA had to be evaluated separ-
ately. Having three MDT levels we got six groups, con-
taining 60 plans each.
Table 2 Average values of the evaluation grouped by the modified parameters
Plan Group CTV H PTV Dmin R-PTVm Dmax R D50 B D50 MU
A. SA 6.1 ± 1.6 59.0 ± 1.6 50.1 ± 2.4 37.0 ± 3.7 37.8 ± 11.4 553 ± 74
DA 6.1 ± 1.5 58.5 ± 1.9 49.0 ± 2.3 34.9 ± 3.0 37.0 ± 10.3 708 ± 65
B. C 0° 6.7 ± 1.7 58.5 ± 1.9 50.0 ± 2.5 35.8 ± 3.8 37.2 ± 11.1 655 ± 105
C 45° 5.5 ± 1.1 59.0 ± 1.6 49.2 ± 2.3 36.1 ± 3.3 37.6 ± 10.7 605 ± 97
C. MDT 80 s SA 6.5 ± 2.0 58.7 ± 1.7 50.7 ± 2.6 39.1 ± 4.0 39.1 ± 11.9 541 ± 85
MDT 110 s SA 5.9 ± 1.5 59.2 ± 1.3 50.0 ± 2.2 36.6 ± 3.2 37.6 ± 11.4 554 ± 67
MDT 150 s SA 5.9 ± 1.0 59.0 ± 1.6 49.6 ± 2.2 35.3 ± 2.8 36.7 ± 11.0 564 ± 67
MDT 80 s DA 6.0 ± 1.5 58.8 ± 1.6 48.9 ± 2.3 34.9 ± 3.9 37.2 ± 10.3 696 ± 63
MDT 110 s DA 6.1 ± 1.5 58.5 ± 1.9 49.3 ± 2.3 34.8 ± 3.0 36.9 ± 10.5 710 ± 65
MDT 150 s DA 6.1 ± 1.6 58.2 ± 2.1 48.9 ± 2.2 35.1 ± 3.1 36.9 ± 10.3 717 ± 68
D. GS 2° 6.5 ± 1.9 58.8 ± 1.8 49.8 ± 2.7 36.4 ± 4.1 38.1 ± 11.1 650 ± 107
GS 4° 5.9 ± 1.3 59.0 ± 1.6 49.5 ± 2.2 35.7 ± 3.4 37.2 ± 10.9 626 ± 104
GS 6° 5.9 ± 1.3 58.4 ± 1.8 49.4 ± 2.2 35.8 ± 3.0 36.8 ± 10.8 614 ± 99
E. IMRT 6.0 ± 0.7 58.4 ± 1.7 51.9 ± 1.4 44.3 ± 2.6 41.2 ± 13.3 498 ± 25
The first column contains the identifying capital letter for the corresponding paragraph in the results section. Average values and empirical standard deviation are
given for the homogeneity H to the CTV (CTV H), the minimum dose to the PTV (PTV Dmin), the maximum dose to the posterior rectum (R-PTVm Dmax), the median
dose to the rectum (R D50) and urinary bladder (B D50), and the MU. Dose values are given in Gy, H in%.
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geneity in the CTV for MDT 80 s was significantly
worse than for MDT 150 s and MDT 110 s. Also the
minimum dose to the PTV was in this group signifi-
cantly lower than for MDT 110 s. The values for the
maximum dose to the posterior rectum differed all sig-
nificantly. Similar were the results for the median dose
to the rectum, all differences being highly significant.
The average of the median values for the urinary bladder
was significantly higher the lower the MDT is. The MU
decreased with the MDT, significant comparing MDT
150 s with the two other groups and not significant in
the last comparison with p = 9.9% (MDT 110 s versus
MDT 80 s). 16 plans with MTD 150 s complied with the
DVO, less in the two other groups (10 respectively 11).
In the DA groups the minimum dose to the PTV reached
in average the best value for MDT 80 s, which was signifi-
cantly better than with MDT 150 s. The MU decreased
with the MDT, but with p=8.6% (MDT 150 s versus MDT
110 s) not significant in one case, highly significant for the
other two comparisons. The absolute number of plans
meeting the DVO was nearly equal in each group: 12
(MDT 150 s), 13 (MDT 110 s), 12 (MDT 80 s).
Gantry spacing
Three groups with a GS of 2°, 4° and 6° were evaluated,
containing 120 plans each. The average of the homogen-
eity to the CTV was highly significant higher for GS 2°
and identical for the two other groups. The average
values for the minimum dose to the PTV were rather
close, revealing the group with GS 6° significantly lower
versus GS 2° and highly significant compared to GS 4°.Rather close values were found for the maximum dose
to the posterior rectum, two pairings differing signifi-
cantly, GS 2° versus GS 4° and GS 2° versus GS 6°. Similar
were the relations for the median dose to the rectum, giv-
ing significant differences in two pairings GS 2° versus GS
4° and GS 2° versus GS 6°. In the urinary bladder the
values for the median dose were significantly different for
GS 4° versus GS 6° and highly significant for the other two
cases. The MU decreased with increasing GS. Here all dif-
ferences were highly significant. The least plans meeting
the DVO were found with GS 6° (21), the incidence in the
two other groups was nearly equal: 26 (GS 4°), 27 (GS 2°).
IMRT
This group contains only ten plans, because the para-
meters of VMAT optimization are not applicable. Table 2
lists the results in the last line.
Graphical evaluation
In a last step for each parameter combination the plans
of the ten different patients were evaluated and the aver-
age values for the specified parameters graphically
depicted. Our examples (Figure 1) show the bar charts
of the endpoints, which did not meet the specified DVO
in every case as average over ten plans. For the sake of
clarity, the bars of the groups with collimator 0° have
been omitted, as it had been shown above that they gave
poorer results. The minimum dose in the PTV was only
met in two groups, [SA, MDT 110 s, GS 2°] and [SA,
MDT 110 s, GS 4°]. Two groups with DA technique
remained just under the prescribed value of 59.4 Gy:
[DA, MDT 80 s, GS 2°] and [DA, MDT 80 s, GS 4°].
Figure 1 Maximum dose to the posterior rectum (a.) and minimum dose to the PTV (b.) for different groups of plans with single arc
(SA) respectively dual arc (DA) technique, maximum delivery times (MDT) of 150 s, 110 s, and 80 s. The colour indicates the gantry
spacing; the last bar represents the values of the IMRT group. The experimental standard deviation is indicated by error bars. Average values for
10 patients.
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80 s, GS 6°] reaching 59.3 Gy. Furthermore these
five groups fulfilled the DVO for the posterior rectum.
Figure 2 shows the dose distributions for one specific
IMRT plan, and two VMAT plans ([DA, MDT 80 s,
GS 4°] and [SA, MDT 110 s, GS 4°]).Plan verification
The four groups resulting as the optimal groups of
VMAT from the graphical evaluation, the just men-
tioned group with GS 6° [SA, MDT 80 s, GS 6°] andthe IMRT group were selected for plan verification.
Table 3 shows the average values and standard devia-
tions for the delivery times and the percentage of pix-
els out of range.Discussion
The results of the SA and DA comparison do not show
a clear advantage of one technique over the other.
Nevertheless the differences are highly significant: a
slight benefit for SA at the minimum dose in the PTV
which is yet below the specified value in the DVO is in
Figure 2 Dose distributions in three planes (first row: transversal, second row: sagittal, third row: coronal) for one specific patient. The
PTV is delineated in red, the CTV in orange. The IMRT plan is shown in the left column, VMAT [DA, MDT 80 s, GS 4°] in the central column and
VMAT [SA, MDT 110 s, GS 4°] in the right column.
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most cases the minimum dose to the PTV is localized in
the posterior region. Keeping the minimum dose here is
correlated to a higher dose to the rectum. The DA tech-
nique favours the dose reduction by focusing on one half
of the PTV for each arc. This is promoted by a higher
MDT. A decrease of the objective weight for the poster-
ior part of the rectum and an increase of the weight for
the minimum dose in the PTV might improve the DA
results. This could be a future step to find an optimal
set of DVO.Table 3 Results of the measurements
Plan group Delivery time in s Pixels out of range in %
SA, MDT 110 s, GS 2° 123 ± 6 1.8 ± 1.2
SA, MDT 110 s, GS 4° 124 ± 7 2.5 ± 0.8
DA, MDT 80 s, GS 2° 252 ± 26 1.1 ± 1.6
DA, MDT 80 s, GS 4° 210 ± 8 2.6 ± 1.6
SA, MDT 80 s, GS 6° 86 ± 1 3.5 ± 1.9
IMRT 417 ± 33 2.3 ± 1.1
Average values and standard deviation of the delivery times and percentage
of pixels out of range in the gamma evaluation with γ> 1 (3 mm, 3%) for four
groups of VMAT plans and for the IMRT group.SA optimization comes out with fewer MU than DA,
because DA focuses on one half of the PTV for each arc.
Fewer MU for SA treatments are an indicator for shorter
treatment times. Additional time is also needed by the
record and verify system and the control system of the
linear accelerator to prepare the second arc. These cir-
cumstances could be confirmed in the plan verification
measurements: The treatment times for the selection of
SA were all smaller than 2 min 15 s, whereas all DA
treatments took more than 3 min 10 s up to nearly
5 min and are therefore above the level of three minutes
where considerable organ movements might occur. The
studies of Ghilezan [39] and Nederveen [40] have shown
an influence of the delivery time on intrafraction organ
motion: the longer the fractional treatment lasts the
higher is the risk of anatomic deviation. Kupelian [41]
argued with this potentially mismatch for daily image
guidance and adaptive radiotherapy. In contrast actually
there exists no defined standard recommendation for
online correction in daily practice when using a VMAT
technique for treating prostate cancer. An option to in-
crease the minimum dose to the PTV in two arcs might
be using orthogonal collimators for each arc. However,
DA is not possible with different collimator values.
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that an angle of 45° should be preferred to an angle of 0°. It
is first advantageous for the dose distribution; this might be
explained by the hypothesis that the leaves of the MLC in
parallel opposed beams move in orthogonal directions and
therefore these beams are not redundant [29]. Furthermore
Otto explains [16] that without collimator rotation only a
single leaf pair can be used to modulate the intensity within
one CT slice. And second the number of MU is 8% lower
with collimator 45° than using a collimator angle of 0°
which can be explained by the fact that with collimator 45°
it is possible to irradiate the right and left side of the PTV
at the same time sparing the rectum and urinary bladder in
the centre, which is not possible with collimator 0°.
For SA treatments a MDT of 80 s seems to be too
short to achieve an acceptable dose distribution. All
evaluated dose parameters were in most cases signifi-
cantly worse than in the two other groups. Only for the
number of MU the best value is achieved. This is not
surprising, as there are only two options for the
optimizer to reduce the treatment time: higher dose
rates and fewer MU. They are closely interconnected
during the optimization process [26]. Although a higher
value than 80 s for the MDT is necessary, the decision
between MDT 110 s and MDT 150 s is not clear without
ambiguity: the dose distribution in the CTV and PTV is
nearly equivalent, the doses to the OAR are a little bit
higher for MDT 110 s, but the MU are lower than for
MDT 150 s. A slight advantage for MDT 150 s might be
derived from the incidence of plans meeting the end-
points. However, regarding the importance of short
treatment times as discussed above and the slight differ-
ence in the dose values a MDT 110 s seems preferable,
which is affirmed by the graphical evaluation.
The decision in the DA groups is clear: the signifi-
cantly highest minimum dose to the PTV is achieved
with MDT 80 s in two arcs, yielding very similar results
for the homogeneity to the CTV and the dose values to
the OAR without statistically significant differences and
again the lowest number of MU which is statistically sig-
nificant. Consequently the shortest MDT provides the
best results.
It might be supposed that for a given MDT all delivery
times shorter are considered by the optimizer. Our mea-
surements indicate that this maximum is exploited. A
long MDT results in more arc sections with a dose rate
at the lower bound allowing less modulation between
the control points. Therefore plans with a longer MDT
can be worse than others with a shorter one.
Analyzing the results of the GS comparison we find
the best value for the minimum dose to the PTV for GS
4°, here the group with GS 6° has the significantly lowest
value. However, in this group we achieve the signifi-
cantly lowest median dose to the urinary bladder andthe lowest number of MU. Nevertheless the advantage
of GS 4° versus GS 2° is quite small and might only be
traced back to the lower modelling accuracy and might
disappear in delivery. Regarding the results of the mea-
surements (Table 3) we find the better accordance for
the γ value the smaller the GS. However this is only sig-
nificant for the DA technique (p = 1.0%), not significant
(p = 6.8%) for the SA technique using MDT 110 s, either
for GS 6° compared to the other SA measurements. The
passing rates are similar as at Feygelman et al. [32] be-
tween 95.6% and 100.0% for GS 2°, 94.5% and 99.6% for
GS 4° and 93.7% and 99.6% for GS 6°. The increase of
the number of pixels failing the gamma criterion can be
explained by the worse modelling of the continuous
movement using a coarser gantry resolution. This model,
the small-arc approximation, has theoretically been
described by Webb and McQuaid [42]. We conclude
that the approximation is still valid for GS 4°, when we
compare the passing rates with IMRT, which are nearly
the same. According to Feygelman et al. [32] and also
suggested by Bzdusek et al. [25] we would use the largest
GS consistent with good dosimetric results (GS 4°) to
minimize the calculation time. Furthermore in this
group nearly as many plans complied with the DVO (26)
as in the GS 2° group (27). Only 21 were found with GS
6°. Consequently GS 6° is not recommended for VMAT
planning of prostate cancer.
The IMRT calculations lack of a similar systematic
variation of parameters as done for VMAT and therefore
detailed statistic intercomparisons would not be appro-
priate. As the main parameters and DVO were taken
(and adapted) from an IMRT study [27] the results
should be quite characteristic. At most one might there-
fore expect an advantage for the IMRT plans. On the
contrary to [25] no modifications to the DVO were
made to improve VMAT plans. Figure 1 and Table 2
show that all VMAT groups with collimator 45° give
comparable or better results for target volumes and
OAR. IMRT attains the lowest number of MU. That is a
discrepancy to other prostate planning studies referring
to RapidArcW [12-14], but for the most part it is due to
the fact that the number of MU in the mentioned stud-
ies with sliding window IMRT technique is higher than
ours with step-and-shoot. This has also been observed
by Alvarez-Moret et al. [18]. They also report that for
equal or slightly more MU even a DA technique takes
only 30% of an IMRT delivery time, for SA it is only
15%. Dobler et al. [19] list one prostate case with a time
reduction from a seven field IMRT to a SA VMAT plan
to 43% at comparable MU. Table 3 shows that our
results for a larger number of patients confirm this
benefit with statistical significance with a time reduction
to around 50% for DA and to about 30% respectively
20% for SA.
Treutwein et al. Radiation Oncology 2012, 7:108 Page 9 of 10
http://www.ro-journal.com/content/7/1/108It might be a surprise that higher MU are not gener-
ally related to improved plan quality. Obviously add-
itional MU are not always exploited in smaller MLC
apertures for better dose modulation. A similar effect
has not only been observed in an IMRT TPS intercom-
parison [43], IMRT planning study comparisons of dif-
ferent algorithms within the same TPS [27,28,44], but
also in the VMAT comparison of Palma et al. [14].
Surely there remains some potential to improve the
algorithm.
Up to now the TPS does not offer the option of dy-
namic collimator rotation, which is technically available
on the Elekta SynergyWS linear accelerator. As Webb has
shown [45] this would help to avoid “parked gaps” for
closed leaf pairs, which are needed during the treatment,
but cannot be parked below the fixed diaphragm due to
limited leaf speed. Avoiding such ‘unwanted fluence’
might be a next step to improve dose distributions in
VMAT plans.
The results of this planning study may in detail be valid
only for the chosen set of DVO. However the references
[16,32] have shown that authors using different equipment
and protocols but similar algorithms have achieved com-
parable results regarding GS and collimator angle. Al-
though the majority of the plans failed the DVO, it could
be shown that all planning aims are met using an appro-
priate set of parameters. The DVO for the rectum and for
the PTV are somehow counterworking goals which are
not met for all settings, as also was found by Crijns et al.
[11], where all five RapidArc planning approaches failed
achieving the rectum maximum dose.Conclusion
With the implementation of VMAT in the OncentraW
MasterPlan system many parameters must be kept in
mind. For prostate planning there is a clear outcome
that a collimator angle of 45° is advantageous. The plan
quality and dosimetric results for GS 2° and 4° are com-
parable, but GS 4° reduces calculation time. SA treat-
ments allow the fastest delivery in less than 2.5 min
which is advantageous with respect to intrafractional
organ movement, gaining a short delivery time and the
best dose distribution with MDT 110 s. DA offers lower
doses to the rectum with delivery times between 3 min
and 5 min. Here MDT 80 s gives the best results.Abbreviations
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